Xenon Pharmaceuticals Stock - Analyst consensus and outlook mid-2026
17.06.2026 - 19:06:45 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 19:05 CET. Details in the imprint.
Xenon Pharmaceuticals (CA98420N1050) is a mid-cap neurology-focused biotech whose shares trade on Nasdaq under the ticker XENE. With no fresh ad-hoc release or major filing today, the spotlight falls on the company’s analyst consensus and operational setup in mid-2026.
All news and data on Xenon Pharmaceuticals stock
Key figures, filings and prior coverage on Xenon Pharmaceuticals stock are compiled in our topic section and on the company’s investor-relations page.
What consensus data show
Across Wall Street, Xenon Pharmaceuticals stock carries a broad Buy rating consensus, with MarketBeat citing 17 covering analysts and an average twelve-month price target around $77.20 per share. This implies material upside from recent trading levels according to the same source.
Within that group, target prices span from approximately $55.00 at the low end to $100.00 at the high end, reflecting differing views on execution risk in the neurology pipeline. The consensus stance is that investors should buy XENE shares, based on these compiled recommendations.
Wednesday focus on operations
Xenon’s business model centers on developing treatments for neurological conditions, a space where phase 2 and phase 3 readouts often drive sharp repricing once data emerge. One industry overview notes upcoming late-stage catalysts in the next few quarters for the ticker XENE.
For a development-stage biotech with no approved products yet, the operational focus is on progressing trials, managing cash burn and maintaining alignment with partners. On balance, the current consensus suggests the market is assigning tangible value to Xenon’s later-stage assets and clinical execution potential.
How the company makes money
Xenon Pharmaceuticals currently generates little recurring product revenue and instead invests heavily in research and development, particularly in neurology drug candidates. The company’s long-term goal is to commercialize its own therapies or secure value-enhancing partnership deals in key indications once clinical data mature.
Where the stock trades today
According to recent Nasdaq trading data aggregated by MarketBeat, Xenon Pharmaceuticals shares last changed hands around the low-to-mid-$50 range in June 2026, with consensus targets implying clear potential upside from this level. The stock trades on Nasdaq in US dollars.
Key facts on Xenon Pharmaceuticals stock
- Company: Xenon Pharmaceuticals Inc.
- ISIN: CA98420N1050
- WKN: A115D7
- Ticker: XENE
- Venue: Nasdaq
- Price (as of 06/17/2026, 17:00 UTC): low-to-mid-$50 range (intraday) USD
- Market cap: mid-single-digit billion USD range (mid-2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: not a member of the S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
